Forest Ray

NEW YORK – Empress Therapeutics sees the next wave of small-molecule medicines reflected in the drug-like behavior of metabolites produced by the human microbiome.

NEW YORK – Polygenic risk scores (PRS) inched closer to clinical adoption over the past year, with several studies demonstrating their clinical utility and feasibility of implementing them into clinical workflows.

NEW YORK – Epigenetics company Volition sees a path towards expansion into East Asian markets, beginning with Taiwan, following the publication of

NEW YORK – Enrollment recently began for a prostate cancer screening program sponsored by the Veterans Administration aimed at determining whether genetic testing can improve prostate cancer screening.

NEW YORK – Geisinger College of Health Sciences hopes to advance its clinical translational genomics capabilities with a scalable population genomics

NEW YORK – A study of over 450,000 opioid-exposed veterans determined that a US Food and Drug Administration-cleared assay failed to meet "reasonable

NEW YORK – Biofidelity is hoping to improve minimal residual disease (MRD) testing and cancer patient monitoring with the rollout of its Enspyre sample enrichment platform.

NEW YORK – Cancer diagnostics firm SeekIn sees a path towards greater accuracy and lower costs for multi-cancer early detection (MCED) testing via

NEW YORK – After making significant strides in lowering solid organ transplant rejection rates through use of pharmaceuticals and nucleic acid-based